Comparision of Oral Misoprostol and Dinoprostone Gel for Induction of Labour in Term Prelabour Rupture of Membrane by Sulekha, B
1 
 
COMPARISION OF ORAL MISOPROSTOL AND 
DINOPROSTONE GEL FOR INDUCTION OF LABOUR IN 
TERM  PRELABOUR  RUPTURE  OF MEMBRANE 
Dissertation submitted to 
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY 
In partial fulfillment of the regulations 
For the award of the degree of 
M.S. BRANCH-II 
OBSTETRICS AND GYNECOLOGY 
 
 
 
 
 
KILPAUK MEDICAL COLLEGE 
CHENNAI 
MAY 2019 
  
2 
 
BONAFIDE   CERTIFICATE 
This is to certify that the dissertation entitled “COMPARISION OF 
ORAL MISOPROSTOL AND DINOPROSTONE GEL FOR 
INDUCTION OF LABOUR IN PRELABOUR RUPTURE OF 
MEMBRANE AT TERM”  is  a  bonafide record of work  done by 
Dr.SULEKHA.B in  Kilpauk Medical college, Chennai during the period 
February 2018 to September 2018 under the guidance of 
Prof.Dr.T.S.MEENA., M.D.,DGO., Professor of Obstetrics and Gynaecology, 
Government Kilpauk  Medical College in  partial  fulfilment  of  requirement of 
MS degree in Obstetrics and Gynaecology degree examination of The 
Tamilnadu Dr. M.G.R Medical University to be held in May 2019. 
 
Dr.T.S.MEENA,M.D.,DGO., 
The Professor, 
Government Kilpauk Medical 
College&  Hospital,  
Chennai – 600 010 
 
Dr.K.L.MALARVIZHI, MD.,DGO., DNB 
Prof & HOD, Dept. Of Obstetrics & 
Gynaecology, Government Kilpauk 
Medical College&  Hospital,  
Chennai – 600 010 
 
Dr.P.VASANTHAMANI, 
MD.,DGO.,MNAMS.,DCPSY.,MBA, 
THE DEAN,  
Government Kilpauk Medical College&  Hospital,  
Chennai – 600 010 
  
3 
 
DECLARATION 
I  Dr.SULEKHA.B, Post graduate, Department of Obstetrics and 
Gynaecology, Government Kilpauk Medical college, solemnly   declare   that   
this   dissertation   entitled “COMPARISION OF ORAL MISOPROSTOL 
AND DINOPROSTONE GEL FOR INDUCTION OF LABOUR IN 
TERM PRELABOUR RUPTURE OF MEMBRANE” was done by me at 
Government Kilpauk Medical College during 2016-2019 under the guidance 
and supervision of Prof.Dr.T.S.MEENA, M.D.,DGO., Professor Department 
of  Obstetrics and  Gynaecology, Government Kilpauk Medical College. This 
dissertation is    submitted  to  the  Tamil  Nadu   Dr. M.G.R. Medical  
University   towards  the  partial  fulfilment  of  requirements  for  the  award  
of  M.S.  Degree in Obstetrics  and  Gynaecology (Branch-II).  
 
 
Place: Chennai-10     Dr.SULEKHA.B, 
Date:                 Postgraduate student, 
Dept. Of  Obstetrics & Gynaecology,   
Govt. Kilpauk Medical College,       
Chennai-10. 
             
  
4 
 
 
ACKNOWLEDGEMENT 
I am thankful to our Dean Dr.P.VASANTHAMANI, M.D., DGO., 
MNAMS., DCPSY, MBA, Government Kilpauk Medical College, Chennai for 
allowing me to conduct the study and  use the facilities and clinical materials 
available in the hospital. 
It is my greatest pleasure to express my gratitude and thank 
Prof.Dr.K.L.MALARVIZHI, M.D.,DGO., DNB, Professor & Head, 
Department of Obstetrics and Gynaecology, Government Kilpauk Medical 
College& Hospital for her valuable guidance, interest, encouragement and the 
constructive ideas which she provided  for this study. 
I sincerely thank our chief Dr.T.S.MEENA, M.D., DGO., Professor, 
Department of Obstetrics and Gynaecology, Government Kilpauk Medical 
College& Hospital for her support, guidance and encouragement. 
I thank all my other Professors, Assistant Professors and paramedical 
Staffs of this Department of Obstetrics and Gynaceology, Kilpauk Medical 
College, Chennai-600010, without whom this would not have been possible. 
I sincerely thank Dr.Padmanabhan, Ph.D, for his constant support during 
this study and for his help in the statistical analysis of data and results. 
 
5 
 
I would like to thank all my fellow post graduates for helping me 
accomplish this. 
I sincerely thank all my patients for their cooperation . 
Last, but not the least, I thank my family and God Almighty for the 
blessings showered onto me.           
  
6 
 
CONTENTS 
1. INTRODUCTION 1 
2. AIMS OF STUDY 3 
3. REVIEW OF LITERATURE 4 
4. MATERIALS AND METHODS 29 
5. RESULTS 32 
6. DISCUSSION 69 
7. SUMMARY 75 
8. CONCLUSION 76 
9. BIBLIOGRAPHY 77 
10. ANNEXURES 79 
 
 
1 
 
INTRODUCTION 
Pre labor  rupture  of  membranes (PROM) is defined as   spontaneous 
rupture  of fetal membranes after 37 completed weeks and before labour onset. 
PROM is a common occurrence with an incidence of 10%  and at least 
60% of cases of PROM occur at term. 
Genital tract infection and associated inflammatory changes are  
responsible for many instances of PROM. Other less consistent associations 
might be cigarette smoking, cocaine abuse, intrauterine DES exposed women 
and possible nutritional deficiencies of ascorbic acid, copper, zinc, and iron. 
The diagnosis can be made through a combination of  history, physical 
examination and specialized testing. 
Management of PROM is still controversial   and involves a balance 
between expectant management and intervention. However induction of labour 
with prostaglandins compared with expectant management reduces the risk of 
maternal sepsis and neonatal complications.Various agents are available for 
induction of labour, mainly prostaglandins and oxytocin.They are used in 
combination  and according to Bishop score. 
Prostaglandins  are  the  agents to soften the unripe cervix independent 
of uterine activity. Induction of labour is artificial or non-spontaneous  
initiation  of  uterine  contractions  that  leads to progressive  cervical  
dilatation and effacement resulting in delivery  of baby or products of 
conception. 
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Dinoprostone is expensive and heat labile. An intense cold chain is to be 
maintained to achieve the  desirable effects. Owing  to  hot  climate , storage 
problems significantly reduce its  efficacy. Exclusive vaginal route also limits 
the use in PROM as  the  risk  of sepsis increases.   
Misoprostol is a synthetic E1 methyl analogue prostaglandin. It is cheap, 
stable at room temperature and effective   in initiating uterine contractions. The 
ease of  multiple  routes  of administration (oral, vaginal, sublingual and  rectal) 
and rapid onset of  action  make   it  a  better option for induction of labour. 
The advantage of oral misoprostol with particular reference to prelabour 
rupture of membranes is the avoidance of  repeated vaginal examinations to 
minimize the risk of maternal and  fetal sepsis. 
Our study is done  to compare the safety and efficacy of oral 
misoprostol  with that of dinoprostone gel for induction of labour in PROM at 
term pregnancy and to monitor maternal and fetal complications. 
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AIM OF THE STUDY 
 
The  present study is undertaken to study  the safety and efficacy of  
misoprostol and dinoprostone for induction of labour in term PROM. 
 
OBJECTIVES:  
 
1) To study the effect on labour induction and compare the induction – 
delivery interval  between 2 drugs. 
2) To compare the mode of delivery between 2 groups. 
3) To compare the fetal and maternal adverse effects between 2 drug groups. 
4) To compare the maternal and fetal outcome between 2 drug groups. 
5) To assess the cost effectiveness between 2 drugs.   
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REVIEW OF LITERATURE 
AMNIOTIC MEMBRANE 
The human foetal membranes is composed of inner amnion and outer 
chorion (Bourne 1962) 
Amnion is an avascular structure of thickness 0.2 – 0.5mm. It provides 
almost all of the tensile strength of the membranes. The Amnion at term is a 
tough and tenacious but pliable membrane. The development of the 
components of the amnion that protects against rupture or tearing is vitally 
important to successful pregnancy outcome. 
Borne (1962) described five separate layers of amniotic tissues. They are 
1) Single layer of cuboidal epithelial cells. 
2) Basement membrane. 
3) Acellular compact layer composed of I, III, V interstitial collagens. 
4) Row of fibroblast like mesenchymal cells. 
5) Acellular zona spongiosa. 
Intact membranes prevents ascending infection as it forms an effective 
barrier. They maintain a fluid environment on which foetus depends upon for 
its survival. They facilitate cervical dilatation and effacement. Membranes are 
rich source of glycerophospholipids containing Arachidonic acid, which are 
precursors of prostaglandins like PGE2 and PGF2α. 
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AMNIOTIC FLUID 
Speculative theories about the origin of amniotic fluid: - 
1) Initially the fluid is formed from the primitive cells around the amniotic 
vesicle. 
2) Later there is transudate of fetal extra cellular fluid through the skin and 
umbilical cord. 
3) Diffusion to some extent occurs through the amniotic membrane. 
4) In second trimester when the skin becomes keratinised fetal urine and 
secretions from tracheobronchial tree contributes to major volume of 
amniotic fluid. 
5) Amniotic fluid volume is about 50ml at 12 weeks, 400ml at 20 weeks, 
1000ml at 36 weeks and 800ml at 40 weeks. 
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FUNCTIONS 
1) Amniotic fluid cushions and protects the fetus from physical trauma. 
2) It distends the amniotic sac and allows further growth and free 
movement of the fetus. 
3) It serves to maintain an even temperature. 
4) When appropriately tested, it provides information about fetal maturity. 
It promotes surfactant synthesis during labour. 
5) It forms a hydrostatic wedge, which helps in dilation of the cervix. 
6) When the membranes are intact, it prevents interference with placental 
circulation during uterine contractions. 
7) It prevents ascending infection to the uterine cavity at the end of first 
stage of labour by flushing and bactericidal action. 
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RISK FACTORS FOR PROM 
1.REMEDIABLE RISK FACTORS 
• Cervico vaginitis 
• Incompetent cervix 
• Cigarette smoking 
• prenatal Diagnostic procedures like amniocentesis etc 
• Coitus, Mineral and vitamins deficiencies, cervical examinations * 
Lacks conclusive confirmation 
2. NONREMEDIABLE RISK FACTORS 
• Prior PROM or preterm delivery 
• Prior cervical surgical procedure 
• Vaginal bleeding –abruptioplacentae, placenta previa etc 
• Ehlers Danlos syndrome 
• Fetal gender (Male)  
Lacks conclusive confirmation 
PHYSIOPHARMACOLOGY OF LABOUR 
Labour is a multifactorial process, which involves myometrial 
contrations, cervical ripening and dilation, and expulsion of fetus and placenta 
is an orderly manner. Both hormonal and paracrine factor have been implicated 
in the mechanisms of parturition. These include progesterone, estrogen, 
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oxytocin, prostaglandins, relaxin, second- messengers, corticosteroids,        
calcium ions and sympathomimatic amines.  
The myometrium and cervix  
The uterus is composed of two anatomically distinct but functionally 
related parts, the myometrium and cervix. During pregnancy the contractility of 
the myometrium is usually diminished to accommodate and protect the 
growing products of conception, where as the cervix forms a light sphincter to 
ensure the integrity of pregnancy. 
Close to term, myometrial activity increases and cervix undergoes 
ripening by which it becomes soft, distensible and partially dilated. 
Simultaneously with the initiation of labour contractions, the cervix dilates as a 
result of the increased compliance and rising intrauterine pressure and allows 
birth to occur. 
Structure and Function of Myometrium  
The uterus consists of three layers of myometrial smooth muscle. It 
undergoes substantial growth in weight and intrauterine volume during 
pregnancy; the smooth muscle cells are embedded in extra cellular matrix 
composed of gap junctions, which are sites of electrical and metabolic 
couplings. Gap junctions are characterized by low electrical impedance (that is, 
high conductivity), which allows rapid spread of action potential, facilitating 
the synchronization of contractile activity. Gap junctions increase in number at 
term. 
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Regulation of Myometrial Contractility 
The basic contractile apparatus of the uterus consists of actin and 
myosin filament, which forms the actomyosin. Phosphorylation of light chains 
by myosin light chain kinase, promotes contraction. Muscle contraction is 
controlled by the contraction of calcium ions in the surrounding cytoplasm. 
Peptides 
Oxytocin stimulates myometrial contraction in late pregnancy. It also 
promotes myometrial contractility through stimulation of PGE2 release. The 
principal site of stimulation is the decidua or endometrium, and it is associated 
with increased phosphoinositide turn over. Oxytocin induces the synthesis of 
the second messenger IP3, which causes the release of intracellular calcium. 
Relaxin may promote uterine relaxation during pregnancy but in labour 
it may bring about cervical maturation without interfering with uterine 
contractility. 
Adrenergic stimulation: - 
The human myometriun contains subclasses of both alpha- 
adrenoceptors and beta- adrenoceptors. Stimulation of alpha- receptors causes 
uterine contraction, whereas stimulation of beta- receptors promotes uterine 
relaxation. Oestrogen treatment results in reduced myometrial sensitivity to 
beta-agonist induced relaxation, which is antagonized by progesterone. A 
family of proteins called GTP- binding proteins or G- proteins regulates         
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the actions. In late pregnancy a switch to alpha-receptor dominance                  
from beta- receptor dominance occurs. 
Prostaglandins: 
Prostaglandins of the E and F types can stimulate the uterus from the 
early stages of gestation and terminate pregnancy at all stages, thus differing 
from oxytocin. Seven different types of receptors have been described in 
human uterus. 
All uterine tissues have the ability to synthesize Prostaglandins, 
synthesis is enhanced by estradiol and oxytocin where as progesterone blocks 
this increase. 
 Structure and function of cervix: 
The uterine cervix is a complex and heterogeneous organ that undergoes 
extensive changes throughout gestation and parturition 10. It is a unique valve 
responsible for keeping the fetus inside the uterus until the end of gestation and 
for its safe passage to the outside world during labour. The cervix is dominated 
by fibrous connective tissue. It is composed of an extra cellular matrix 
consisting predominantly of collagen with elastin and proteoglycans, and a 
cellular portion consisting of smooth muscle and fibroblasts, epithelium and 
blood vessels. 
The relative ratio of connective tissue to smooth muscle is not uniformly 
distributed thought the length of the cervix. The distal portion has a greater 
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ratio of connective tissue to smooth muscle than the upper cervical portion 
closer to the myometrium. Extensive remodelling of the cervix occurs from 
early gestation to the postpartum period. 
The process of remodeling appears to be due to collagenases, elastases 
and matrix metalloproteinases. Another important structure involved in 
collagen structure is the presence of a small molecular weight proteoglycon, 
decorin. Decorin is a small dermatan sulphate proteoglycan that coats collagen 
fibrils. Cervical cells secrete decorin during late pregnancy. When the ratio of 
decorin to collagen increases; it probably causes a dispersal of collagen fibrils 
leading to disorganization of collagen fibres. 
As pregnancy advances concentration of collagen decreases. There is 
noted to be an infiltration of the cervix by macrophages and neutrophils. These 
cells are a prominent source of proteases, collagenases and elastases. 
Furthermore, fibroblasts and smooth muscle cells and interleukins also 
contribute to the increase in degradative enzymes which are further stimulated 
by hyaluronic acid. Hyaluronic acid is produced by fibroblasts and stimulated 
by interleukins and prostaglandins. It has an important role in increasing the 
water content of the cervix at term, which leades to a loosening and dispersal of 
fibres. It also has a role in neovascularisation, a process noted in cervical 
ripening. 
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Cervical scoring Methods: 
In 1964 Bishop described a scoring system for determining a patient’s 
suitability for elective induction of labour 15. He advocated vaginal 
examination rather than rectal examination. 
Factor 
Score 
0 1 2 3 
Dilatation(cm) 0 1-2 3-4 5-6 
Effacement(%) 0-30 40-50 60-70 80 
Station -3 -2 -1 or 0 +1 to +2 
Consistency Firm Medium Soft - 
Position Posterio
r 
Mid Anterior - 
 
Bishop found that elective induction was safe and uniformly successful 
when the score was 9 or more. 
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Fields proposed one more scoring system at the obstetrical society of 
philadelphia in 1965 16. 
Factor 
Score 
0 1 2 
Attitude towards 
induction 
Objects or fears Hesitates , accepts Enthusiastic 
Estimated fetal 
weight(g) 
<2,500 Uncertain >2,500 
Uterine tone on 
palpation 
Flaccid Some tone Firm contraction 
Softness of cervix Firm Somewhat soft Soft 
Effacement (%) <80 80 >80 
Position of cervix Posterior 45degree to vaginal 
Axis 
Towards vulva 
Station of presenting 
part 
-2 or higher -1 to 0 +1 or lower 
Dilatation(cm) 0-1 2-3 >3 
Recent vaginal 
discharge 
No discharge Increased Blood tinged 
 
Fields found that induction with a score of 10 or less resulted in a 
doubling of the complication rate and increase in the average duration of 
labour and the operative delivery rate 16. 
 
  
14 
 
Burnett proposed the modified bishop score 17. Patients who had a score 
of 9 or 10 on this scale, delivered within 4 Hours, most within 2 hours 
according to his observation. 
Factor Score 
0 1 2 
Dilatation(cm) <1-5 1.5-3 >3 
Station -2 or higher -1 0 or lower 
Position Posterior Mid Anterior 
Effacement(cm) 1.5 or more Intermediate 0.5 or less 
Consistency Firm Intermediate Soft 
 
Weighted bishop’s score by Friedman 
 
  
Factor Unweigted 
Simple  
Weighting 
Complete 
Weighting 
Dilatation(cm) 0-3 X 2 X 4 
Station 0-3 X 1 X 2 
Position 0-3 X 1 X 2 
Effacement(cm) 0-2 X 1 X 2 
Consistency 0-2 X 0 X 1 
Range of scores 0-13 0-14 0-30 
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Modified Bishops’s score (Calder 1974) 
  0 1 2 3 
Dilatation of 
cervix(cm) 
<1 1-2 2-4 >4 
Length of 
cervix(cm) 
>4 2-4 1-2 <1 
Station -3 -2 -1/0 +1/+2 
Consistency of 
cervix 
Firm Average Soft - 
Position of 
cervix 
Posterior Mid- anterior - - 
Score 0-5 unfavourable, 6-12 favourable 
 
PROSTAGLANDINS1 
 
Prostaglandins were first described by Von Euler. Prostaglandins are 20 
carbon atom fatty acids with cyclopentane ring and two side chains. 
 
8 6 4 2   COOH 
10     20 
 12 14 16 18  
 
 
Prostanoic Acid. 
 
Prostaglandins are named A to I depending upon the structure of the 
carbon ring. The side chains of prostaglandins have one or more double bonds 
the number of double bonds are indicated by the numerical Subscript, E.g., 
PGE1, PGE2 and PGE3 
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Biosynthesis 
  
Prostaglandins are synthesized from essential unsaturated fatty acids37. 
Among them aracidonic acid (AA) is the most important one. The first step in 
the bio-conversion of aracidonic acid to prostaglandins (PGE2 and PGF2 α), 
Prostacyclins (PGI 2) and thromboxanes ( T X A2) is the formation of cyclic 
endoperoxides, i.e Prostaglandins G and H. The enzyme responsible for the 
conversion of AA to PGH2 is known as fatty acid cyclooxygenase or 
Prostaglandin end peroxide synthetase. PGG2 and PGH2 are further converted 
non enzymatically into PGE2, PGF2α, PGI2 and TXA2. These conversions are 
extremely rapid and occur in all mammalian tissues. 
Metabolism1 
Natural Prostaglandins is metabolized rapidly.The main route of 
metabolic degradation is by oxidation at the site of carbon 15 that gives to 15 
keto Prostaglandins, which are biologically inactive. A further reduction of the 
double bond at carbon 13 leads to the formation of 15 keto 13, 14 dihydro 
Prostaglandins. The enzymes involved in the initial conversion are found in the 
lungs, liver and kidney. The estimated half-life of PGE2 is about 15 seconds 
and that of the metabolite eight minutes. 
Prostaglandin E and Prostaglandin F Receptors 
Receptors for PGE and PGF are present in both pregnant and non- 
pregnant uteri. There are eight types and subtypes of PG receptors. They 
include thromboxane A2, prostacyclin, PGF and PGD receptors and four 
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subtypes of PGE receptors (EP1, EP2, EP3, & EP4) These receptors are 
encoded by different genes. They are coupled to G- Proteins and the receptor – 
G- protein complexes are coupled to different effectors systems. The receptors 
are specific for the pentane ring structure. 
Both PGE2 and PGE22 receptors increase in the myometrium at the 
beginning of labour. The PGF receptor is expressed mainly in luteal cells. It 
has 362 amino acids arranged in seven hydrophobic transmembrane helical 
segments. 
There are four subtypes of PGE receptors. They couple to two major 
effectors pathways leading to increased intracellular calcium and muscle 
contraction (EP1) to stimulation of the adenyl cyclase system leading to muscle 
relaxation (EP2 and EP4) and to inhibition of the adenyl cyclase system leading 
to muscle contraction (EP3). The distribution of PGE receptors is different 
among different tissues. There are PGE receptors in cervix, but their 
concentration is lower than in the myometrium. Prostaglandin E and F receptor 
vary in their affinity for their substances. In human myometrium the 
prostaglandin receptor have 10 times greater affinity for PGE than for PGF, 
and PGE, and PGE2 have a higher affinity for the PGE2 receptor than 
PGE2 itself. 
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Prostaglandin Analogues 
Due to rapid inactivation of natural prostaglandins, analogues have been 
developed that are resistant to inactivation, while retaining than biological 
activity. The following are the Prostaglandin analogues. 
-15(s) –15 methyl- PGE2(carboprost) 
-16-Phenoxy –10-tetranor-PGE2 sulfonylamide (sulprostone) 
-16,16 – dimethyl-trans-∆2-PGE, (gemeprost) 
-9-deoxo-16, 16-dimethyl-9 methylene-PGE2 (meteneprost) 
They provide an opportunity to formulate vehicles for different routes of 
administration; where as primary prostaglandins have to be administered by the 
intravenous route. 
Pharmacological Actions1 
The best known actions can be summarized as follows: - 
-Stimulation of smooth muscle leading to either contraction or relaxation, 
depending upon the receptors involved. 
-Changes in the cervical tissue 
-Inhibition of gastric acid secretion and cytoprotection 
-Inhibition and induction of platelet aggregation 
-Increase in vascular permeability 
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-Thermoregulation 
-Modification of steroid genesis in the adrenals and gonads. 
-Inhibition of hormone induced lipolysis 
-The release of neurotransmitter in the peripheral nervous system and 
potentiation of the action of biogenic amines. 
Prostaglandins are potent stimulators of the uterine myometrium at all stages of 
pregnancy. 
MISOPROSTOL 
Misoprostol 38, a derivative of PGE1, has become widely used in 
pregnant women for cervical ripening and induction of labour. Misoprostol 
originally was designed for the treatment of gastric ulcers secondary to the 
administration of non steroidal anti- inflammatory agents. 
Misoprostol has been produced by bringing about an alteration in the 
chemical structure of the naturally occurring compound PGE1 39, there by 
making it orally stable and clinically useful. The chemical formula of 
misoprostol is C22 H38O5 or (+_) (Methyl C13E) 11,16 dihydroxy, 16-
methyl-9-OXO-Prost-13-enoate. By relocating the 15- hydroxy group to the 
adjacent 16 positions and addition of a methyl group to carbon 16, misoprostol 
has been developed. 
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The C-16 hydroxyl group is less susceptible to action 
of 15- dehydrogenase enzyme. 
 
                    O 
CH2(CH2)5COOCH3 
 
 
H CH3 
 
C=C-CH2-C(CH2)3CH3 
 
    OH 
 
Structure of misoprostol 
Misoprostol is mainly manufactured as oral tablets as 100 and 200microgram 
tablet and can be used orally, vaginally and rectally. It is stable in ambient 
temperature unlike other prostaglandins and has a long shelf life. 
Following oral administration, this drug is absorbed quickly and then 
de-esterified into its active pharmacological from misoprostrol acid, less than 
90 % of which remains bound to serum protein. Misoprostol acid is responsible 
for different clinical activities. 
Concentration of this metabolite reaches its peak approximately by next 
30 minutes and declines rapidly through. Maximum plasma concentration is 
diminished when the drug is taken with food and total availability of the  active 
metabolite is reduced by concomitant antacid. Primary site of metabolism of 
this drug is in liver and less than 1% of this metabolite is excreted in urine. 
Dose of the drug needs adjustment when used in patients with liver disease 
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whereas it is not required in-patient with renal disease and not on dialysis. The 
drug has no known drug interactions. 
Vaginal administration has the advantage of reducing gastrointestinal 
side effects and exerts profound effect on reproductive tract, there by this route 
has been used extensively in different clinical conditions related to obstetrics 
and gynaecology 40. 
After application in the posterior fornix, plasma concentration reaches 
peak by one to two hour and then slowly declines unlike oral absorption, 
slower increase and lower peak plasma concentration of misoprostol is noted. 
Uses of Misoprostol 
 First trimester termination of pregnancy 
 Second trimester termination of pregnancy 
 Cervical ripening and induction of labour 
 Control of post partum hemorrhage, 
 Before gynecological procedures like, Before hysteroscopy 
Before endometrial biopsy Before intrauterine insemination. 
Dinoprostone (PGE2) 
Mechanism of Action  
Exogenous local application of PGE2 results in cervical ripening by at least 3 
mechanisms. 
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The first mechanism is by softening the cervix by altering the 
extracelluar ground substance of the cervix, PGE2 increases the activity of 
collagenase which reaches maximum activity at 2 hours after application in 
patients of multiparity and 4 hours after application in patients of nulliparity. 
Elastase also increases to a maximum level nearly seven fold more than 
baseline at 4 hours. Total glycosaminoglycan, dermatan sulphate, and 
hyaluronic acid levels increase during PGE2- induced cervical ripening. This 
time dependent collagen degradation by collagenases and other proteases and 
increase in hyaluronic acid results in a cervix that is soft and more pliable.  
It relaxes the cervical smooth muscle, thus facilitating cervical dilation. 
The fundal myometrium responds to PGE2 by contracting. 
Gap junction formation that is necessary for labour is facilitated by 
PGE2 42. It also facilitates post-cervical ripening and induction by preparing 
the uterus to produce- coordinated contractions with lower oxytocin doses. 
Vaginal PGE2  
PGE2 is also used by vaginal route for labour induction and cervical ripening, 
it is available in three different forms. 
1) Pessary 
2) Tablets 
3) Gel 
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Pessaries or suppositories were first developed for the management of second 
trimester, and later found useful for cervical ripening and labour induction. 
Vaginal tablets are also available for induction of labour. 
Gel preparations were used by vaginal route and intracervical route for 
cervical ripening and labour induction. They were either home- made 
containing 2.5 or 5mg PGE2, 2mg, 4mg in cellulose base and commercially 
available triacetin based gel containing 1-3 mg. Pessaries/ tablet/ gel are placed 
in the posterior fornix and the patient should be asked to lie in supine position 
for at least one hour. The action of the vaginal Prostaglandins can be seen 
within 5-7 hours and most patients go in to spontaneous labour. 
Side effects of prostaglandins: 
Common adverse effects are nausea, vomiting, diarrhoea, abdominal 
cramps, chills, fever which are dose dependant. When used for induction of 
labour prostaglandins can cause : 
• Tachysystole, defined as six or more uterine contractions in 10 min for 
two consecutive 10 minute periods. 
• Hypersystole, defined as single contraction of atleast 2 minutes in 
duration. 
• Uterine hyperstimulation, defined as Tachysystole or Hypersystole 
associated with a nonreassuring fetal heart rate pattern. Nonreassuring 
fetal heart rate pattern is said to be there when persistent or recurring 
episodes of sever variable decelerations, late decelerations, or prolonged 
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fetal bradycardia, or a combination of decreased beat to beat variability 
and a decelerative pattern occur. 
Expected problems in Induction 
• Failure to labour induction. 
• Unforeseen disproportion. 
• Prematurity. 
• Sepsis. 
• Cord compression and 
• Accidental hemorrhage. 
Diagnosis of PROM 
1.History of leak or sudden gush of fluid from the vagina and a sterile 
speculum examination may reveal the leakage of liquor. 
2.The nitrazine Test 
It has an accuracy of 90 to 95 percent. It differentiates the alkaline pH of 
amniotic fluid (7 to 7.5) and acid pH of vaginal fluid (4-4.5) 
3. The fern Test 
The fluid is dried on a slide and observed under microscope. Fern 
pattern is seen due to crystallization of sodium chloride in amniotic fluid. 
4.The Nile blue Sulphate Test 
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The presence of desquamated cells from the fetal skin, which stains 
orange, indicates ruptured membrane. 
5.Intra amniotic dye instillation 
Instillation of indigo carmine, Evans blue, sodium flourescein and 
examination of vaginal fluid on pad for the presence of dye after the few hours 
is useful. 
6.AMNIOSCOPY 
It may reveal the absence of membranes. This is not done routinely. 
7.DIAMINE OXIDASE TEST 
Diamine oxidase is produced by decidual cells, enters amniotic fluid and can be 
detected by paper strips. 
8. Heat Test 
Endo cervical material is heated on a glass slide and the color of the 
residue is noted. A white residue indicates the presence of amniotic fluid and a 
brown one indicates its absence. 
9.Measurement of alpha feto protein in vaginal fluid is a recent test. 
10.Monoclonal antibodies to fetal fibronectin or used to detect the presence of 
amniotic fluid in vaginal secretions. 
11.ULTRA SOUND 
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To know the amount of liquor left behind and for fetal maturity, USG is done. 
12. AN IMMUNOASSAY KIT TEST which detects ILGFBP 1( insulin like 
growth factor  binding  protein-1)will be done.ILGFBP 1 is present 100-1000 
times more concentration in amniotic fluid than serum,urine,vaginal secretions 
which help us to confirm the presence of amniotic fluid. 
Karim et al  1972  was  the  first one  to use  prostaglandins  for  
induction  of  labour. They used  Prostaglandins  intravenously. 
Luis Sanchez – Ramos, Anita H – Chen and Colleagues 1997 found that 
Misoprostol  usage significantly reduces Induction – delivery interval in labour 
Induction in term PROM  patients and concluded that Misoprostol is effective, 
cheap and safe. 
In Dec 2000 ACOG reaffirmed its recommendation for the use of 
Misoprostol because  of proven safety and efficacy. 
Kulshreshtha et al 2007 conducted  prospective randomised study on 
misoprostol intravaginally 100µg  4th hrly Vs dinoprostone gel 0.5 mg 12 th 
hrly and concluded that misoprostol is an effective and safe drug for induction 
and augmentation of labour compared to dinoprostone. 
Fatima A Naz M et al 2013 conducted experimental study on oral 
misoprostol in term PROM  50µG  4 th hrly 6 doses and concluded oral 
misoprostol as safe method of induction with good fetomaternal outcome. 
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Jonna Malathi and Venigalla Sunita 2015 conducted study on 
misoprostol vaginally 25µg and dinoprostone gel  0.5 mg 6th hrly and 
concluded that misoprostol is equally efficacious and has similar fetomaternal 
outcome as dinoprostone gel. 
 I. ACOG committee on obstetric practice have emphasized the following 
clinical practices in order to minimize the risk of uterine hyperstimulation and 
rupture in patients undergoing cervical ripening and induction of labour. 
1). If misoprostol is used, 25microg should be considered for initial dose. 
2). Doses should not be administered more frequently than 3-6 hours. 
3). Misoprostol should not be used in patients with a previous caesarian 
delivery or a prior major uterine surgery. 
II. FIGO guidelines 2017 for induction of labour:-  
Misoprostol recommended in dose of 25µg pv every 6 hours or  
25µg po every 2 hours. 
III.   WHO recommendation of induction of labour included oral  
Misoprostol 25 µg 2 hrly for induction of labour and not recommended 
for those with previous cesarean section. 
IV. FDA IN 2002  approved a new labeling for  misoprostol for its use in  
cervical ripening and induction of labour. 
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V.Cochrane pregnancy and childbirth group review 2003 on a systematic 
review of 62 randomized trials states that.  
-Lower dosage regimens had lesser uterine hyper stimulation with fetal heart 
changes and fewer low APGAR scores at 5 min and a non significant trend to 
fewer admission in NICU. They suggested that surface trials involving 
misoprostol should be 
-Randomised, double blind 
-Dose of vaginal misoprostal not more than 25mg 4th to 6th hourly. 
-Sufficient sample size to detect moderate difference in important uncommon 
complications such as severe perinatal morbidity and mortality and meconium 
stained liquor to be included an outcome measure. 
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MATERIALS AND METHODS 
STUDY DESIGN : PROSPECTIVE RANDOMISED CONTROL STUDY. 
PERIOD OF STUDY:-FEBRUARY  2018-SEPTEMBER  2018 
PLACE OF STUDY:- Labour ward ,Govt Kilpauk Medical College,  Chennai. 
 STUDY POPULATION:- Antenatal  patients getting admitted in labour 
ward. Govt. Kilpauk Medical College, Chennai.  
SAMPLE SIZE:- Determined by statistical analysis. Statistical analysis was 
done using chi square test and student ‘t’ test used in appropriate places. About 
100 women were randomized to either Misoprostol or Dinoprostone. 
Diagnosis of prelabour rupture of membranes made on the basis of 
history, clinical examination, obstetric examination , speculum examination . 
 Inclusion criteria:-  
1.Pregnant wowen at term  ≥ 37 weeks gestation. 
2.Singleton pregnancy. 
3.Cephalic presentation. 
4.PROM  > 4hrs.. 
5. Reactive CTG(cardiotocography) trace. 
6. Bishop score <6. 
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Exclusion criteria:- 
                      1. Symptoms and signs suggestive of chorioamnionitis. 
                      2. Prior uterine surgery(caesarean section, myomectomy),. 
                      3.multiparous 3 or more 
                      4.Bad obstetric history. 
                      5.Severe IUGR. 
                      6.Severe oligohydramnios. 
                      7.Multiple pregnancy. 
8.Other contraindications to vaginal delivery like placenta previa  
and cephalopelvic disproportion. 
                      9.Malpresentation. 
                      10.Medical disorders complicating pregnancy, GDM, pre  
eclampsia, heart disease, renal disease, pulmonary disease. 
                       11. Active vaginal bleeding. 
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METHODOLOGY 
The study was approved by the ethical committee. Informed consent 
obtained from the patients before induction. For patients entering into study 
detailed relevant history regarding obstetrical, medical and surgical obtained 
and general examination, obstetric  and pelvic examination done. All confirmed  
PROM patients > 37 weeks of gestation after fulfilling all inclusion and 
exclusion criteria sterile per vaginal examination to assess bishop score  fetal 
evaluation with CTG, USG for liquor status, colour of liquor and duration of 
draining p/v assessed. 
After reactive CTG term prom patients will be randomly  selected and 
induced with oral misoprostol 25 µg 4th hrly and dinoprostone gel 0.5mg 6th 
hrly in ratio 1:1 till maximum of 3 doses or until active labour starts. Fetal and 
uterine monitoring was performed on all patients. Bishop’s score was assessed 
every 4 hours in Misoprostol group and every 6 hours in Dinoprostone group. 
If contractions were not adequate, in active phase of labour syntocinon 
drip was started with 2.5 U in 500ml ringer lactate with 2 mu/min and 
increased in geometric fashion every 30 min till 3 contractions were observed 
in 10 min period each lasting for 45-60 seconds upto a maximum of 40mu/min. 
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RESULTS 
 
AGE GROUP * GROUP 
 
   GROUP  
   MISOPROSTOL DINOPROSTONE Total 
AGE 
GROUP 
<=25 Count 17 13 30 
% within 
GROUP 
34.0% 26.0% 30.0% 
26-30 Count 33 37 70 
% within 
GROUP 
66.0% 74.0% 70.0% 
 Total Count 50 50 100 
% within 
GROUP 
100.0% 100.0% 100.0% 
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CHI SQUARED=  0.762    P=  0.383   NOT  SIGNIFICANT. 
• In both the groups more than 60% observed in 26-30 yrs age group, 
33(66%) in misoprostol group and  37(74%) in dinoprostone group. 
• No statistically significant differences in age distribution of patients 
assigned  to  the 2 groups.  
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BOOKING STATUS * GROUP 
 
 
   GROUP  
   MISOPROSTOL DINOPROSTONE Total 
BOOKING 
STATUS 
BOOKED Count 46 47 93 
% within 
GROUP 
92.0% 94.0% 93.0% 
NO Count 4 3 7 
% within 
GROUP 
8.0% 6.0% 7.0% 
 Total Count 50 50 100 
% within 
GROUP 
100.0% 100.0% 100.0% 
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CHI  SQUARE=  0.154 P=  0.695  NOT  SIGNIFICANT. 
• Among the Misoprostol group 92% cases and among the Dinoprostone 
group 94 % cases were booked. 
• There is no statistically significant difference in booking status of the 
patient assigned  to the 2 groups. 
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GRAVIDA * GROUP 
 
 
   GROUP  
   MISOPROSTOL DINOPROSTONE Total 
GRAVID
A 
1 Count 25 21 46 
% within 
GROUP 
50.0% 42.0% 46.0% 
2 Count 25 29 54 
% within 
GROUP 
50.0% 58.0% 54.0% 
 Total Count 50 50 100 
% within 
GROUP 
100.0% 100.0% 100.0% 
 
  
37 
 
 
CHI  SQUARE=  0.644   P=  0.422  NOT  SIGNIFICANT. 
 
• In the Misoprostol group 50%cases are primigravida and 50% cases are 
multigravida whereas in Dinoprostone group 42% cases are 
primigravida and 58% cases are multigravida. But there is no 
statistically significant difference in parity assigned to 2 groups. 
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NO.OF  DOSES * GROUP 
 
   GROUP  
   MISOPROSTOL DINOPROSTONE Total 
NO.OF  
DOSES 
1 Count 11 12 23 
% within 
GROUP 
22.0% 24.0% 23.0% 
2 Count 31 29 60 
% within 
GROUP 
62.0% 58.0% 60.0% 
3 Count 8 9 17 
% within 
GROUP 
16.0% 18.0% 17.0% 
 Total Count 50 50 100 
% within 
GROUP 
100.0% 100.0% 100.0% 
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CHI  SQUARE=  0.169  P=  0.919  NOT  SIGNIFICANT.  
• In our study most of the cases(60%) required 2 doses of drug.62% 
among the Misoprostol group and 58% among the Dinoprostone group. 
• Only 8(16%) cases in Misoprostol group and 9(18%) cases in 
Dinoprostone group required 3 doses of drug. 
• There is no statistically significant difference between the two groups 
with respect to no of doses required. 
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MODE OF  DELIVERY * GROUP 
 
   GROUP  
   MISOPROSTOL DINOPROSTONE Total 
MODE OF  
DELIVERY 
LSCS Count 4 5 9 
% within 
GROUP 
8.0% 10.0% 9.0% 
NVD Count 46 45 91 
% within 
GROUP 
92.0% 90.0% 91.0% 
 Total Count 50 50 100 
% within 
GROUP 
100.0% 100.0% 100.0% 
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CHI  SQUARE=  0.122  P=  0.727  NOT  SIGNIFICANT 
• In our study 91 %cases successfully delivered vaginally,9 % went for 
lscs.92%(46)  cases in the Misoprostol group and 90% (45) cases in the 
Dinoprostone group delivered vaginally. Only 4 cases in Misoprostol 
group- 2 in view of fetal distress of which 1 due to uterine 
hyperstimulation,1 in view of failed induction.and 5 cases in 
Dinoprostone group -2 in view of failed induction and 3 in view of fetal 
distress were done  lscs. 
• There is no statistically significant difference in the groups with respect 
to mode of delivery. 
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USE OF  OXYTOCIN * GROUP 
 
   GROUP  
   MISOPROSTOL DINOPROSTONE Total 
USE OF  
OXYTOCIN 
NO Count 40 24 64 
% within 
GROUP 
80.0% 48.0% 64.0% 
YES Count 10 26 36 
% within 
GROUP 
20.0% 52.0% 36.0% 
 Total Count 50 50 100 
% within 
GROUP 
100.0% 100.0% 100.0% 
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CHI  SQUARE=  11.111  P=  0.001  SIGNIFICANT. 
 
• In our study only 10 (20%)cases in Misoprostol group required oxytocin 
for augmentation of labour whereas in Dinoprostone group 26 (52%) 
cases required oxytocin drip.So less use of oxytocin drip when 
Misoprostol is used for induction of labour which is significant as 
evidenced by P value of 0.001 and chi square value of 11.111. 
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INDUCTION DELIVERY INTERVAL * GROUP 
 
   GROUP  
   MISOPROSTOL DINOPROSTONE Total 
INDUCTION DELIVERY 
INTERVAL 
4 Count 11 1 12 
% within GROUP 22.0% 2.0% 12.0% 
5 Count 6 0 6 
% within GROUP 12.0% .0% 6.0% 
6 Count 2 0 2 
% within GROUP 4.0% .0% 2.0% 
8 Count 10 5 15 
% within GROUP 20.0% 10.0% 15.0% 
9 Count 4 3 7 
% within GROUP 8.0% 6.0% 7.0% 
10 Count 6 21 27 
% within GROUP 12.0% 42.0% 27.0% 
11 Count 5 0 5 
% within GROUP 10.0% .0% 5.0% 
12 Count 2 4 6 
% within GROUP 4.0% 8.0% 6.0% 
14 Count 1 0 1 
% within GROUP 2.0% .0% 1.0% 
16 Count 2 14 16 
% within GROUP 4.0% 28.0% 16.0% 
18 Count 0 1 1 
% within GROUP .0% 2.0% 1.0% 
20 Count 1 1 2 
% within GROUP 2.0% 2.0% 2.0% 
 
Total Count 50 50 100 
% within GROUP 100.0% 100.0% 100.0% 
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CHI SQUARE=  43.143  P=  0.000<0.001  SIGNIFICANT 
• In our study within 8 hrs of induction 58 % (29)women among the 
Misoprostol group delivered whereas only 12 %(6) women delivered among 
the Dinoprostone group .After 10 hrs of induction 78% (39) women delivered 
among the Misoprostol group and 60% (30) women delivered among the 
Dinoprostone group.8% among the Misoprostol group and 32 % among the 
Dinoprostone group delivered only after 12 hours of induction.  
• So there is faster induction of labour when misoprostol is used for induction 
and induction delivery interval is significantly reduced in Misoprostol group 
as evidenced by P value of  <0.001 chi square value 43.134. 
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UTERINE HYPERSTIMULATION* GROUP 
 
   GROUP  
   MISOPROSTOL DINOPROSTONE Total 
UHS NO Count 49 48 97 
% within 
GROUP 
98.0% 96.0% 97.0% 
YES Count 1 2 3 
% within 
GROUP 
2.0% 4.0% 3.0% 
 Total Count 50 50 100 
% within 
GROUP 
100.0% 100.0% 100.0% 
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CHI  SQUARE  =0.344  P=  0.558  NOT  SIGNIFICANT. 
• Uterine hyperstimulation is tachysystole or hypersystole associated with a 
nonreassuring fetal heart rate pattern.1 case in Misoprostol group and 2 cases 
in Dinoprostone group had hyperstimulation .All 3 women underwent lscs 2 
Babies had 1 min apgar 8/10 and 1 baby had 1 min apgar 6/10.Babies 
followed up postnatally and baby discharged in good condition from neonatal 
unit. 
• No statistically significant difference noted in the 2 groups. 
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INTRAPARTUM FEVER * GROUP 
 
 
   GROUP  
   MISOPROSTOL DINOPROSTONE Total 
IP FEVER NO Count 48 47 95 
% within 
GROUP 
96.0% 94.0% 95.0% 
YES Count 2 3 5 
% within 
GROUP 
4.0% 6.0% 5.0% 
 Total Count 50 50 100 
% within 
GROUP 
100.0% 100.0% 100.0% 
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CHI  SQUARE=  0.211  P=  0.646  NOT  SIGNIFICANT.  
• In our study 2 cases in Misoprostol group and 3 cases in Dinoprostone group 
had minor reactions like fever, nausea, vomiting which resolved without any 
treatment There is no statistically significant difference with respect to minor 
drug reactions in both the groups. 
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RD * GROUP 
 
   GROUP  
   MISOPROSTOL DINOPROSTONE Total 
RD NO Count 49 47 96 
% within 
GROUP 
98.0% 94.0% 96.0% 
YES Count 1 3 4 
% within 
GROUP 
2.0% 6.0% 4.0% 
 Total Count 50 50 100 
% within 
GROUP 
100.0% 100.0% 100.0% 
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CHI  SQUARE=1.042  P=  0.307  NOT  SIGNIFICANT 
 
• In our study 4 babies had  mild respiratory distress after delivery 1 in 
Misoprostol group and 3 in Dinoprostone group. All babies followed 
postnatally in neonatal unit and were discharged in good condition. 
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BIRTH ASPHYXIA * GROUP 
 
   GROUP  
   MISOPROSTOL DINOPROSTONE Total 
BA NO Count 48 48 96 
% within 
GROUP 
96.0% 96.0% 96.0% 
YES Count 2 2 4 
% within 
GROUP 
4.0% 4.0% 4.0% 
 Total Count 50 50 100 
% within 
GROUP 
100.0% 100.0% 100.0% 
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CHI  SQUARE-  0.000  P=  1.000 
• In our study  4 babies, 2  in Misoprostol group 2 in Dinoprostone group 
developed birth asphyxia of which 1 in both groups were delivered by lscs and 
2 by vaginal delivery. There is no statistically significant difference seen. 4 
babies recovered and discharged with mother in good condition. 
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EARLY ONSET SEPSIS * GROUP 
 
   GROUP  
   MISOPROSTOL DINOPROSTONE Total 
EOS NO Count 49 46 95 
% within 
GROUP 
98.0% 92.0% 95.0% 
YES Count 1 4 5 
% within 
GROUP 
2.0% 8.0% 5.0% 
 Total Count 50 50 100 
% within 
GROUP 
100.0% 100.0% 100.0% 
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CHI  SQUARE=  1.895  P=  0.169 
 
• In our study 5 babies developed early onset sepsis 1 in Misoprostol group and 
1 in Dinoprostone group and were treated with iv antibiotics in neonatal unit 
and recovered. There is no statistically significant difference noted. 
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1 MIN APGAR <6 * GROUP 
 
   GROUP  
   MISOPROSTOL DINOPROSTONE Total 
1 MIN APGAR 
<6 
NO Count 49 48 97 
% within 
GROUP 
98.0% 96.0% 97.0% 
YES Count 1 2 3 
% within 
GROUP 
2.0% 4.0% 3.0% 
 Total Count 50 50 100 
% within 
GROUP 
100.0% 100.0% 100.0% 
 
No statistically significant difference noted between the groups with respect to 
neonatal compliacations as evidenced by CHI  SQUARE=  0.344  P=  0.558  . 
Among the 3 babies which had apgar <6/10 1 in Misoprostol group and 1 in 
Dinoprostone group was delivered by lscs in view of fetal distress and 1 in 
Dinoprostone group was delivered by vaginal delivery. 
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RMC  SATISFACTION * GROUP 
 
   GROUP  
   MISOPROSTOL DINOPROSTONE Total 
RMC  
SATISFACTION 
NO Count 1 2 3 
% within 
GROUP 
2.0% 4.0% 3.0% 
YES Count 49 48 97 
% within 
GROUP 
98.0% 96.0% 97.0% 
 Total Count 50 50 100 
% within 
GROUP 
100.0% 100.0% 100.0% 
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 CHI  SQUARE=  0.344  P=  0.558  NOT  SIGNIFICANT.  
 
• In both the groups most of the mothers (97 %) had respectful maternal care 
satisfaction. Only 3 mothers 1 in Misoprostol group and 2 in Dinoprostone 
group were not satisfied who were taken for lscs in view of failed induction 
after 3 doses of drug. 
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FETAL DISTRESS * GROUP 
 
   GROUP  
   MISOPROSTOL DINOPROSTONE Total 
FD NO Count 46 44 90 
% within 
GROUP 
92.0% 88.0% 90.0% 
YES Count 4 6 10 
% within 
GROUP 
8.0% 12.0% 10.0% 
 Total Count 50 50 100 
% within 
GROUP 
100.0% 100.0% 100.0% 
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CHI  SQUARE=  0.444  P=  0.505  NOT  SIGNIFICANT.  
In misoprostol group, 4 patients had fetal distress of which 2 delivered 
vaginally as they  had fetal distress in 2nd stage of labour and 2 patients were 
done lscs. 
In dinoprostone group, 6 had fetal distress of which 3 delivered 
vaginally and 3 patients undergone lscs. 
In both the groups after delivery 2 babies had apgar 6/10 other babies 
had good apgar.So 2 babies required NICU admission. There is no statistically 
significant difference between the 2 groups. 
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LIQUOR * GROUP 
 
   GROUP  
   MISOPROSTOL DINOPROSTONE Total 
LIQUOR CLEAR Count 44 41 85 
% within 
GROUP 
88.0% 82.0% 85.0% 
GRADE 1 Count 6 2 8 
% within 
GROUP 
12.0% 4.0% 8.0% 
GRADE 2 Count 0 5 5 
% within 
GROUP 
.0% 10.0% 5.0% 
GRADE 3 Count 0 2 2 
% within 
GROUP 
.0% 4.0% 2.0% 
 Total Count 50 50 100 
% within 
GROUP 
100.0% 100.0% 100.0% 
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CHI  SQUARE=  9.106  P=  0.028  SIGNIFICANT.  
 
 
• In our study 15 patients were with meconium stained liquor of which all 
6(12%) patients in Misoprostol group had only thin MSL  whereas in 
Dinoprostone group of 9 (18% )patients with MSL -2 were with thick 
MSL,5 with moderate MSL and 2 with thin MSL. Statistically 
significant difference noted in respect to liquor status between the 2 
groups. 
• In Misoprostol group 6 Patients were with thin meconium stained liquor. 
All are NST reactive.  5 patients with thin meconium stained liquor 
64 
 
delivered vaginally.1 patient went for lscs in view of fetal distress after 
2nd dose of misoprostol. 
• In Dinoprostone group, 2 patients were with thick meconium stained 
liquor, 5 patients were with moderate meconium stained liquor ,2 
patients were with thin meconium stained liquor. All are NST reactive.  
2 thick meconium stained liquor patients and 2 moderate meconium 
stained liquor were not in active phase of labour and went in for LSCS, 
3 patients with moderate meconium stained liquor in advanced labour 
delivered by outlet forceps. All patients with thin meconium stained 
liquor delivered vaginally. 
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SUCCESS * GROUP 
Crosstab 
   GROUP  
   MISOPROSTOL DINOPROSTONE Total 
SUCCESS YES Count 46 45 91 
% within 
GROUP 
92.0% 90.0% 91.0% 
NO Count 4 5 9 
% within 
GROUP 
8.0% 10.0% 9.0% 
 Total Count 50 50 100 
% within 
GROUP 
100.0% 100.0% 100.0% 
 
  
66 
 
 
CHI  SQUARE=  0.122  P=  0.727  NOT  SIGNIFICANT 
 
• In misoprostol group 46 patients had successful induction and delivered 
vaginally. 
• In dinoprostone group 45 patients had successful induction and deliverd 
vaginally. 
• There is no statistically significant difference 
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                                                AGE GROUP 
 
GROUP N Mean 
Std. 
Deviation 
Std. Error 
Mean 
AGE MISOPROSTOL 50 25.84 2.469 .349 
DINOPROSTONE 50 26.46 2.460 .348 
 
 
Independent Samples Test 
  t-test for Equality of Means 
   
  
Sig. (2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
AGE Equal variances 
assumed 
.211 -.620 .493 
Equal variances not 
assumed 
.211 -.620 .493 
 
GESTATIONAL AGE 
 
GROUP N Mean 
Std. 
Deviation 
Std. Error 
Mean 
GA MISOPROSTOL 50 38.82 1.004 .142 
DINOPROSTONE 50 38.68 1.058 .150 
 
  
68 
 
 
  t-test for Equality of Means 
  
Sig. (2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
GA Equal variances 
assumed 
.499 .140 .206 
Equal variances not 
assumed 
.499 .140 .206 
 
 
INDUCTION DELIVERY INTERVAL 
 
GROUP N Mean 
Std. 
Deviation 
Std. Error 
Mean 
INDUCTION 
DELIVERY 
INTERVAL 
MISOPROSTOL 50 8.14 3.642 .515 
DINOPROSTON
E 
50 11.82 3.433 .485 
 
Independent Samples Test 
  t-test for Equality of Means 
   
  
df Sig. (2-tailed) 
Mean 
Difference 
INDUCTION 
DELIVERY 
INTERVAL 
Equal variances 
assumed 
98 .000 -3.680 
Equal variances not 
assumed 
97.658 .000 -3.680 
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DISCUSSION 
 In this study synthetic PGE1, analogue oral misoprostol has been 
compared with the time tested PGE2 gel intracervical dinoprostone gel with 
respect to outcome of induction in terms of successs of induction, induction 
delivery interval, mode of delivery, need for oxytocin augmentation, neonatal 
and maternal complications. 
 Misoprostol was used at a dose of 25micrograms 4th hourly, as per 
the recommendations of ACOG committee on obstetric practice, FIGO, WHO 
guidelines and cochrane review 2002; 2003. 
 
TABLE 1 
Dosing regimen 
 
STUDY MISOPROSTOL DINOPROSTONE 
Kulshreshtha  2007 100 microg 4 hrly 0.5 mg 12 hrly 
Fatima A Naz M 2013 50 microg 4 hrly 0.5 mg 6 hrly 
Abraham  et al 2014 25 microg 4 hrly 10 mg vaginal insert single 
application 
Jonna Malathi 2015 25 microg 6 hrly 0.5 mg 6 hrly 
Present study 2018 25 microg 4th hrly 3 
doses 
0.5 mg 6 hrly, 3 doses 
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In the present study 100 patients with PROM were induced with either 
misoprostol or dinoprostone alternately. Patients assigned to PGE1 group 
received 25 micrograms of misoprostol tablet  every 4th hourly, for a maximum 
of 75 micrograms. Patients assigned to PGE2 group received 0.5 mg of 
dinoprostone gel placed intracervically, every 6th hourly for a maximum of 3 
doses. Most of them delivered with 2 doses both in Misoprostol group 21 
(42%) nullipara, 10 (20%) multipara) and in Dinoprostone group 19(38%) 
nullipara, 10 (20%) multipara. 
 
Induction delivery interval(in hours) 
 
STUDY MISOPROSTOL DINOPROSTONE 
Kulshreshtha 2007 11.4 18.9 
Fatima A Naz M 2013 23.9 31.1 
Abraham 2014 13.8 21.1 
Jonna Malathi 2015 14.5 19.2 
Present study 2018 8.14 11.82 
 
 
The induction delivery interval was significantly shorter in the misoprostol 
group as compared to dinoprostone group,8.14 v/s 11.82 hours. 
The induction delivery intervals varied from 11.4 to 23.9 hours for 
misoprostol, to 18.9 to 31.1 hours in the dinoprostone group in different 
studies. The present study is   comparable to previous studies with respect to 
induction delivery interval. 
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Oxytocin Use 
STUDY MISOPROSTOL DINOPROSTONE 
  Kulshreshtha 23.1% 55% 
Fatima A Naz M 2013 Not stated Not stated 
Abraham 2014 63.5% 81.5% 
Jonna Malathi 2015 39.8% 68.7% 
Present study 2018 20% 52% 
 
 
Significantly lesser percentage of patients in the Misoprostol group 
needed oxytocin for labour acceleration as compared to the patients in the 
Dinoprostone group. This finding is observed in the other studies also. The 
reduced need for oxytocin augmentation reduces the inconvenience and the 
patient can remain ambulatory for a longer time without the oxytocin drip. In 
addition, the overall cost for delivery reduces as less dripsets and oxytocin are 
used.  
Caesaerean section rates. 
STUDY MISOPROSTOL DINOPROSTONE 
Kulshreshtha 2007 10% 10% 
  Fatima A Naz M 2013 13.2% 14.3% 
Abraham 2014 25.6% 22.2% 
Jonna Malathi 2015 22.2% 13.0% 
Present study 2018 8% 10% 
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Caesaerean section rate in the two groups did not have any significant 
difference and this comparable to the study by Kulshreshtha and all.. 
In the misoprostol group 8% of patients underwent emergency 
caesaerean section for fetal distress, whereas it was 10% in the dinoprostone 
group. In the dinoprostone group 4% of patients underwent caesaerean section 
for failure to progress. 
 
Maternal side effects. 
STUDY MISOPROSTOL DINOPROSTONE 
Kulshreshtha 2007 
  
Tachysystole 
  
Hyperstimulation 2% 4% 
Fatima A Naz M 2013 
  
Tachysystole 
  
Hyperstimulation 13.2% 2.9% 
Jonna Malathi 2015 
  
Tachysystole 7.8% 1.2% 
Hyperstimulation 1.3% 2.5% 
Abraham 2014 
  
Tachysystole 4% .2% 
Hyperstimulation 2.7% 1.1 
Present study 2018 
  
Tachysystole 11.1% 7.8% 
Hyperstimulation 21.3% 7% 
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There were only 3 cases of hyperstimulation in the study, 1 in 
Misoprostol group and 2 in  dinoprostone group. 
The occurrence of tachysystole and hyperstimulation appeared to be 
dose related since the incidence was decreased with 25 microg 4hourly 
regimen, while the incidence was high  with higher dosing regimen of 
misoprostol as observed in the table. 
Other side effects ranging from nausea, vomiting, diarrhea, fever were 
reported in minority of cases in both the groups in the study. However thes side 
effects were mild and self-limitting. 
One of the most serious complication  with misoprostol use, is  rupture 
uterus.  There was no case of rupure uterus in our study.         
Neonatal complications 
NICU admissions 
STUDY MISOPROSTOL DINOPROSTONE 
Kulshreshtha 2007 0 0 
  Fatima A Naz M  2013 2.6% 8.6% 
 Jonna Malathi 2015 8.2% 8.7% 
Abraham 2014 7.4% 7.0% 
Present study 2018 14% 12% 
 
The incidence of meconium aspiration syndrome was 6% in each group. 
Nicu admissions were 14% and 12% in the groups respectively. Thus neonatal 
outcome was equally good in both the groups. The results among the trials has 
been depicted in the table. 
74 
 
No significant differences observed in terms of tachysystole / Hyper 
tonus / Hyper stimulation between two drug groups. 
Supportive studies are as follows. 
• Fatima A Naz M et al JUMDC issue 1 labour induction with oral 
misoprostol. 
• Lin MG, Ramsey PS and Colleagues in their metaanalysis of 
Misoprostol for labour induction in women with term PROM. 
• Sanchez and Ramos and Colleagues 1993 & 1997 Int J Obstet Gynaecol 
89:4, 133-42. 
This powerful little tablet (Misoprostol) can work wonder and save time, 
energy  and money for many but has to be used with caution and respect. 
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SUMMARY 
 Misoprostol at 25µg dose repeated 4th hourly is an effective, cheap, 
safe and  easy to use labour induction agent. 
 Induction – delivery internal is shorter  in Misoprostol group compared 
to Dinoprostone group 
 No statistically significant difference was observed in caesarean section 
rate between two drug groups. 
 Neonatal outcomes were comparable between both groups. 
 Maternal complications were not significantly different between both 
groups. 
 Misoprostol is cost effective, easy to use and stable at room 
temperature. 
 Misoprostol use is associated with decreased requirement of oxytocin 
for augmentation of labour. 
 The smaller doses (25mcg) of misoprostol is not associated with any 
significant complications like hyperstimulation, fetal distress or rupture 
uterus. 
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CONCLUSION 
 
Misoprostol is an effective, cheap, safe, stable at room temperature and 
easy to use with shorter induction delivery interval  and no major adverse feto 
maternal  reactions with good feto maternal outcome if it is used in appropriate 
dosage for induction of labour in prelabour rupture of membranes at term. 
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STUDY PROFORMA 
 
(COMPARISION OF ORAL MISOPROSTOL AND 
DINOPROSTONE GEL FOR INDUCTION IN PRELABOUR 
RUPTURE OF MEMBRANE AT TERM  ) 
 
1. Name-       Phone no- 
 
2. Age- 
 
3. Gestational age (in weeks)- 
 
4. Ip no- 
 
 
5. Address- 
 
 
6. Socioeconomic status-   
 
                                                                  
7. Menstrual history- 
Age of menarche attainment- 
Regularity of cycle- 
If irregular explain- 
LMP- 
 
 
8. Marital history 
Married since-            years 
Consanguinity- 
 
9. Obstetric history 
Parity-       
History of abortion- 
No of living children- 
Last child birth- 
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10. Presenting complaint-(Complaints of draining pervaginum for how 
long) 
11. Past history- 
 
H/o DM/HTN/TB/ epilepsy/bronchial asthma/drug allergy/Thyroid 
disorder. 
              
            H/o any previous surgeries. 
 
EXAMINATION 
1. Height- 
 
2. Weight- 
 
3. BMI- 
 
4. Blood pressure- 
 
5. Temperature.- 
 
6. General Examination- 
       
7. Obstetric Examination- 
 
8. Per Speculum Examination- 
 
9. BISHOP Score- 
 
10. Utrasound findings (AFI)- 
 
11. CTG Tracing- 
 
BLOOD INVESTIGATIONS: 
     
1. Haemoglobin- 
 
2. Total count- 
 
3. Differential count- 
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4. Random blood sugar- 
 
5. Blood Group and Rh Factor- 
 
6. HIV- 
  
7. VDRL- 
 
8. HBsAg- 
 
9. Urine R/E- 
 
10. Urine  C/S- 
 
11. High Vaginal Swab C/S- 
 
FETOMATERNAL OUTCOME: 
        1.Induction Delivery Interval- 
         
        2.No. of doses required- 
 
        3.Mode of delivery    
                             Vaginal- 
                             Caesarean- 
 
        4.Failed Induction- 
   
       5.Maternal satisfaction- 
 
       6.Maternal Complications 
                               Nausea and Vomiting- 
                               Pyrexia >100 F- 
                               Uterine Hyperstimulation- 
                               Uterine rupture- 
                               PPH- 
 
       7.Fetal Complications 
                        Meconium stained amniotic fluid- 
                        Abnormal ctg- 
                        Low apgar at 5 min- 
                        Still birth-  
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PATIENT INFORMATION SHEET 
 
• We are conducting a study on comparision  of oral misoprostol and 
dinoprostone gel for induction of labour in term PROM 
• in patients attending Government Kilpauk Medical College 
Hospital, Chennai and for that your participation. may be valuable 
to us. 
• The purpose of this study is to study the safety and efficacy of 
misoprostol and dinoprostone gel in PROM and its maternal and 
fetal outcomes . 
• You have been diagnosed as term PROM  and you are an eligible 
candidate for this study. 
• The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or 
presentation resulting from the research, no personally identifiable 
information will be shared. 
• Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are 
otherwise entitled. 
• The results of the special study may be intimated to you at the end 
of the study period or during the study if anything is found 
abnormal which may aid in the management or treatment. 
 
 
 
 
Signature of investigator    Signature of participant 
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PATIENT CONSENT FORM 
 
 
Title of the project:   
Name :      Date : 
Age :      IP No : 
Sex :      Project Patient No : 
 
• The details of the study have been provided to me in writing and 
explained to me in my own language. 
• I confirm that I have understood the above study and had the 
opportunity to ask questions. 
• I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time, without giving any reason, without the 
medical care that will normally be provided by the hospital being 
affected. 
• I agree not to restrict the use of any data or results that arise from this 
study provided such a use is only for scientific purpose(s). 
• I have been given an information sheet giving details of the study. 
 
I fully consent to participate in the above study 
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A STUDY ON SAFETY AND EFFICACY OF ORAL MISOPROSTOL AND 
DINOPROSTONE GEL FOR INDUCTION OF LABOUR IN TERM PROM 
 
பெபபவ	 ெபய :                               வய:  எ : 
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ெகாகிேற	.  
• இ/த ஆ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KEY TO MASTER CHART 
GA –Gestational Age 
RD-Respiratory Distress 
BA-Birth Asphyxia 
IP Fever-Intrapartum Fever 
FD- Fetal distress 
EOS-Early onset sepsis 
RMC-Respectful maternal care satisfaction 
NVD-Normal Vaginal delivery 
LSCS- Lower segment    caesaerean section 
 NICU- Neonatal intensive care unit 
UHS-Uterine  Hyperstimulation 
SL NO NAME GROUP AGE AGE GROUP  IP  NO
BOOKING 
STATUS
GA GRAVIDA
NO.OF  
DOSES
MODE OF  
DELIVERY
USE OF  
OXYTOCIN
INDUCTION 
DELIVERY 
INTERVAL
UHS IP FEVER FD RD BA EOS
1 MIN 
APGAR <6
1 MIN 
APGAR<8
RMC  
SATISFACTI
ON
LIQUOR  
GRADE
1 JOTHI         1 24 1 17256 1 37 1 2 NVD NO 5 NO NO NO NO NO NO NO NO YES C
2 LATHA         1 25 1 17542 1 38 2 1 NVD NO 4 NO NO NO NO NO NO NO NO YES C
3 KAVITHA       1 28 2 17846 1 39 2 2 NVD NO 5 NO NO NO NO NO NO NO NO YES C
4 KALAIVANI     1 27 1 18546 1 40 2 2 NVD NO 5 NO NO YES NO NO NO NO NO YES C
5 LAKSHMI       1 26 1 18874 1 41 2 2 NVD NO 5 NO NO NO NO NO NO NO NO YES C
6 DEEPA         1 29 2 18654 1 41 2 2 NVD NO 5 NO NO NO NO NO NO NO NO YES C
7 KAMATCHI      1 30 2 18544 1 41 2 2 NVD NO 4 NO NO NO NO NO NO NO NO YES C
8 AMMU          1 28 2 12256 1 38 1 2 NVD NO 4 NO NO NO NO NO NO NO NO YES C
9 SUBHA         1 27 1 18542 1 39 1 2 NVD NO 4 NO NO NO NO NO NO NO NO YES C
10 SELVI         1 26 1 16245 1 37 1 3 LSCS NO 16 NO NO NO NO NO NO NO NO YES C
11 MEENA         1 28 2 18478 1 38 1 2 NVD NO 4 NO NO NO NO NO NO NO NO YES C
12 PARVATHY      1 29 2 18957 1 39 2 1 NVD NO 4 NO NO NO NO NO NO NO NO YES C
13 POONGODI      1 26 1 19477 1 40 2 1 NVD NO 4 NO NO YES NO NO NO NO NO YES C
14 ABINAYA       1 27 1 18794 1 39 2 1 NVD YES 4 NO NO NO NO NO NO NO NO YES C
15 NANDHINI      1 26 1 19458 1 38 2 1 NVD YES 4 NO NO NO NO NO NO NO NO YES C
16 ANITHA        1 22 0 19456 1 39 1 3 LSCS YES 20 NO NO YES NO NO NO NO NO NO C
17 VIJAYASHANTHI 1 20 0 19265 1 38 1 2 NVD YES 4 NO NO NO NO NO NO NO NO YES C
18 GOMATHY       1 21 0 20184 1 39 1 2 NVD YES 4 NO NO NO NO NO NO NO NO YES C
19 REVATHY       1 27 1 17852 1 37 1 3 NVD YES 14 NO YES NO NO NO NO NO NO YES C
20 CHITHRA       1 26 1 19654 1 38 1 2 NVD YES 6 NO YES NO NO NO NO NO NO YES C
21 DEEPA         1 24 1 18457 1 39 1 1 LSCS YES 6 YES NO NO NO NO NO NO NO YES C
22 ESTHER        1 23 0 13654 1 40 1 3 NVD YES 16 NO NO NO NO NO YES NO NO YES C
23 DEEPIKA       1 24 1 20187 1 40 1 1 NVD YES 11 NO NO NO NO YES NO NO YES YES C
24 SARALA        1 23 0 20156 1 40 1 2 NVD NO 10 NO NO NO NO NO NO NO NO YES 1
25 NISHANTHINI   1 24 1 21354 1 38 1 2 NVD NO 10 NO NO NO NO NO NO NO NO YES 1
26 CHANTHINI     1 25 1 19846 1 39 1 2 NVD NO 10 NO NO NO NO NO NO NO NO YES 1
27 LATHA         1 26 1 20154 1 37 1 3 NVD NO 10 NO NO NO NO NO NO NO NO YES 1
28 STELLA        1 27 1 20165 1 39 2 1 NVD NO 10 NO NO NO NO NO NO NO NO YES 1
29 BHUVANESHWARI 1 28 2 23415 1 38 2 1 LSCS NO 10 NO NO YES NO NO NO NO NO YES 1
30 JEYALAKSHMI   1 24 1 22189 1 39 2 1 NVD NO 11 NO NO NO NO NO NO NO NO YES C
31 SATHYA        1 25 1 26547 1 38 2 1 NVD NO 11 NO NO NO NO NO NO NO NO YES C
32 SHANTHI       1 28 2 24516 1 39 2 2 NVD NO 11 NO NO NO NO NO NO NO NO YES C
33 CHITHRA       1 27 1 24567 1 37 2 2 NVD NO 11 NO NO NO NO NO NO NO NO YES C
MASTER CHART
SL NO NAME GROUP AGE AGE GROUP  IP  NO
BOOKING 
STATUS
GA GRAVIDA
NO.OF  
DOSES
MODE OF  
DELIVERY
USE OF  
OXYTOCIN
INDUCTION 
DELIVERY 
INTERVAL
UHS IP FEVER FD RD BA EOS
1 MIN 
APGAR <6
1 MIN 
APGAR<8
RMC  
SATISFACTI
ON
LIQUOR  
GRADE
34 SUCILA        1 26 1 21547 1 38 2 2 NVD NO 12 NO NO NO YES YES NO YES YES YES C
35 DEEPA         1 29 2 26548 1 39 1 2 NVD NO 12 NO NO NO NO NO NO NO NO YES C
36 VELVILI       1 30 2 23654 1 40 1 3 NVD NO 8 NO NO NO NO NO NO NO NO YES C
37 SRILEKHA      1 28 2 26548 1 38 1 2 NVD NO 8 NO NO NO NO NO NO NO NO YES C
38 SUGANYA       1 27 1 26547 1 39 2 2 NVD NO 8 NO NO NO NO NO NO NO NO YES C
39 KOKILA        1 26 1 29687 1 40 2 2 NVD NO 5 NO NO NO NO NO NO NO NO YES C
40 DEVI          1 28 2 23654 1 38 2 3 NVD NO 8 NO NO NO NO NO NO NO NO YES C
41 THILAGAVATHY  1 29 2 21456 1 39 2 2 NVD NO 9 NO NO NO NO NO NO NO NO YES C
42 YAMUNA        1 26 1 26548 1 38 2 2 NVD NO 9 NO NO NO NO NO NO NO NO YES C
43 RENUKA        1 27 1 23598 1 39 2 2 NVD NO 9 NO NO NO NO NO NO NO NO YES C
44 LEELA         1 26 1 24987 1 40 2 2 NVD NO 9 NO NO NO NO NO NO NO NO YES C
45 JEYANTHI      1 22 0 26593 1 38 1 2 NVD NO 8 NO NO NO NO NO NO NO NO YES C
46 RANI          1 20 0 27458 1 39 1 2 NVD NO 8 NO NO NO NO NO NO NO NO YES C
47 KOKILA        1 21 0 27569 2 40 1 3 NVD NO 8 NO NO NO NO NO NO NO NO YES C
48 FATHIMA       1 27 1 27898 2 37 1 2 NVD NO 8 NO NO NO NO NO NO NO NO YES C
49 MURUGALAKSHMI 1 24 1 27945 2 38 2 2 NVD NO 8 NO NO NO NO NO NO NO NO YES C
50 PORSELVI      1 23 0 28456 2 39 1 2 NVD NO 8 NO NO NO NO NO NO NO NO YES C
51 LALITHA       1 22 0 28534 2 38 1 2 NVD NO 12 NO NO NO NO NO NO NO NO YES C
52 HEMALATHA     2 20 0 28945 2 39 1 2 NVD YES 12 NO NO NO NO NO NO NO NO YES C
53 INDRA         2 28 2 26541 2 37 2 2 NVD YES 16 NO NO NO NO NO NO NO NO YES C
54 PAVITHRA      2 24 1 23654 1 39 2 2 NVD YES 12 NO NO NO NO NO NO NO NO YES C
55 SENTHAMILSELVI 2 25 1 26987 1 38 2 2 NVD YES 4 NO YES NO NO NO NO NO NO YES C
56 MAHALAKSHMI   2 26 1 26548 1 39 1 3 NVD YES 10 NO YES NO NO NO NO NO NO YES C
57 JENIFER       2 27 1 26543 1 38 2 2 NVD YES 10 NO NO NO NO NO NO NO NO YES C
58 SOUNDARYA     2 29 2 26874 1 39 2 2 LSCS YES 10 YES NO YES NO NO NO NO NO YES 2
59 PRADEEPA      2 25 1 27984 1 37 2 2 NVD YES 8 NO NO NO NO NO NO NO NO YES C
60 VIDYA         2 26 1 27654 1 38 2 1 NVD YES 8 NO NO NO NO NO NO NO NO YES C
61 SURYA         2 27 1 28654 1 39 1 2 NVD YES 8 NO NO NO NO NO NO NO NO YES C
62 RUTHMARY      2 25 1 28653 1 40 1 3 NVD YES 8 NO NO NO NO NO NO NO NO YES C
63 NAYAGI        2 28 2 29465 1 38 1 2 NVD YES 8 NO NO NO NO NO NO NO NO YES C
64 MEERA         2 29 2 29584 1 39 1 3 LSCS YES 9 NO NO YES NO NO NO NO NO YES 3
65 POOVARASI     2 30 2 29635 1 40 1 2 NVD YES 9 NO NO NO NO NO NO NO NO YES C
66 SELVI         2 26 1 29468 1 38 1 2 NVD YES 9 NO NO NO NO NO NO NO NO YES C
67 SEETHA        2 27 1 30215 1 39 1 2 NVD YES 16 NO NO NO NO NO NO NO NO YES C
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68 DURGA         2 24 1 30254 1 38 2 2 NVD YES 16 NO NO NO NO NO NO NO NO YES C
69 HARIPRIYA     2 25 1 30654 1 39 2 1 NVD YES 10 NO NO NO NO NO NO NO NO YES C
70 REVATHY       2 28 2 30589 1 40 2 1 NVD YES 10 NO NO YES NO NO NO NO NO YES C
71 KAMALA        2 27 1 30654 1 38 2 1 NVD YES 10 NO NO NO NO NO NO NO NO YES C
72 VETRISELVI    2 26 1 30874 1 39 2 2 NVD YES 16 NO NO NO NO NO NO NO NO YES C
73 HAMALATHA     2 29 2 31547 1 40 2 2 NVD YES 10 NO NO NO NO NO NO NO NO YES 2
74 BAKYALAKSHMI  2 30 2 31658 1 37 1 2 NVD NO 16 NO NO NO NO NO NO NO NO YES C
75 VIJAYASHANTHI 2 28 2 32547 1 38 2 2 NVD NO 10 NO NO YES NO NO NO NO NO YES 2
76 ASHWINI       2 27 1 32587 1 39 1 1 NVD NO 10 NO NO NO NO NO YES NO NO YES C
77 JEYANTHI      2 26 1 32654 1 40 2 1 NVD NO 10 NO NO NO NO NO NO NO NO YES 2
78 SOPHIA        2 25 1 32698 1 38 1 1 NVD NO 10 NO NO NO NO NO NO NO NO YES C
79 JEGAPRIYA     2 28 2 32987 1 39 2 1 NVD NO 10 NO NO NO NO NO NO NO NO YES C
80 NAVEENA       2 27 1 32875 1 40 1 3 NVD NO 16 NO NO NO NO NO NO NO NO YES C
81 DEVAKI        2 26 1 32698 1 37 2 3 NVD NO 16 NO NO NO NO NO NO NO NO YES C
82 BAKKIYAM      2 29 2 33698 1 38 2 2 NVD NO 10 NO NO YES NO NO NO NO NO YES 1
83 MENAGA        2 30 2 33654 1 39 1 3 NVD NO 20 NO NO NO NO NO NO NO NO YES 1
84 VENDAMPONNU   2 28 2 33985 1 37 2 1 NVD NO 16 NO NO NO NO NO NO NO NO YES C
85 MALLIKA       2 27 1 33654 1 38 2 2 NVD NO 16 NO NO NO NO NO NO NO NO YES C
86 GLORY         2 26 1 34568 1 39 1 2 NVD NO 10 NO NO NO NO NO NO NO NO YES C
87 LAKSHMI PRIYA 2 28 2 34568 1 40 1 2 NVD NO 10 NO NO NO NO NO NO NO NO YES C
88 USHA          2 29 2 34215 1 41 2 1 NVD NO 16 NO NO NO NO NO NO NO NO YES C
89 JAMUNA        2 26 1 35468 1 41 2 2 NVD NO 16 NO NO NO YES YES YES YES YES YES C
90 PUSHPA        2 27 1 35648 1 39 2 2 NVD NO 16 NO NO NO NO NO NO NO NO YES C
91 RADHA         2 26 1 35687 1 38 2 2 NVD NO 16 NO NO NO NO NO NO NO NO YES C
92 MEENATCHI     2 22 0 36874 1 41 1 2 NVD NO 10 NO NO NO NO NO NO NO NO YES C
93 VANI          2 20 0 36548 1 39 1 2 NVD NO 10 NO NO NO NO NO NO NO NO YES C
94 KALIYAMMAL    2 21 0 36498 1 40 2 2 LSCS NO 10 NO NO NO NO NO NO NO NO YES 2
95 KASTHURI      2 27 1 37985 1 38 2 3 NVD NO 10 NO NO NO NO NO NO NO NO YES C
96 THULASI       2 24 1 37564 1 39 2 1 LSCS NO 10 NO NO YES NO NO NO NO NO YES 3
97 VENNILA       2 26 1 38479 1 40 2 2 NVD YES 10 NO NO NO NO NO NO NO NO YES C
98 JENIFER       2 28 2 38975 1 39 1 3 LSCS YES 10 NO NO NO NO NO NO NO NO NO C
99 INDRA         2 29 2 38459 1 38 2 1 NVD YES 16 NO NO NO NO NO NO NO NO YES C
100 SOPHIA        2 30 2 36541 1 37 1 3 NVD YES 18 NO NO NO NO NO NO NO NO YES C
